A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)

This study (WU-KONG21) is testing a combination of two targeted drugs — DZD9008 and AZD4205 — for patients with advanced non-small cell lung cancer (NSCLC) that has a mutation in the EGFR gene (a key driver of certain lung cancers) and has stopped responding to standard treatments. **You may be eligible if...** - You are 18 or older with confirmed locally advanced or metastatic NSCLC - Your cancer has an EGFR mutation - You have received prior standard treatments that have stopped working - You are in good performance status (ECOG 0–1) with a life expectancy of at least 12 weeks - If you have brain metastases, they must be stable and previously treated **You may NOT be eligible if...** - Your lung cancer does not have an EGFR mutation - You have not yet tried standard EGFR-targeted therapies - You have active, unstable brain metastases - You have significant heart, lung, or other organ problems Talk to your doctor to see if this trial is right for you.